ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2521

Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes

Pervin Sanci1, Gokce Kenar2, Berrin Zengin2, Sadettin Uslu3, Aydan Koken3, Handan Yarkan3, Gerçek Can3, Merih Birlik3 and Fatos Onen2, 1Internal Medicine, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 2Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 3Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: axial spondyloarthritis, Disease Activity, metabolic syndrome, psoriatic arthritis and radiography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim of this study is to investigate its relationship with disease activity in patients with PsA. We also evaluated whether an association exists between MetS and axial involvement in PsA.

Methods:

This study included patients with PsA followed in the Rheumatology outpatient clinic at Dokuz Eylul University. Age-matched patients with Takayasu arteritis (TA), an inflammatory systemic disease, were enrolled as diseased controls. The NCEP-ACT III criteria were used to identify subjects with MetS. Disease activity was assessed in patients with PsA by using several parameters including BASDAI, ASDAS, VAS patients’ and physician’ global, Tender and Swollen joint assessment (28/68), DAS28, DAPSA, CPDAI and SPARCC Enthesitis Index. ESR and serum CRP levels were measured. BASFI and BASMI were used to evaluate functional status and HAQ, ASQoL and DLQI to evaluate health and PASI to measure the severity of psoriasis. Hand and pelvis X-rays and sacroiliac joint MRIs were performed when indicated.

Results: There were 104 PsA patients (63.5% F; mean age: 50.9±13.0 years; mean disease duration: 8.69 ±6.5 years) who fulfilled the CASPAR criteria and 28 TA patients (89% F, mean age: 46.3±9.1) who fulfilled the ACR 1990 criteria. The prevalence of MetS was found to be considerably higher in PsA patients compared to TA patients (45.2% and 21.4% respectively, p<0.001). In the comparison of PsA patients with and without MetS, no differences were found regarding treatment frequencies of NSAIDs, glucocorticoids, DMARDs and anti-TNFs and also mean glucocorticoid dosages. PsA patients with MetS had higher BASDAI, BASFI, BASMI, VAS, ASqOL, CPDAI, ASDAS and HAQ scores compared to PsA patients without MetS (Table 1). More patients with syndesmophytes were found among PsA patients with MetS compared to those without MetS (p=0.027). There were no differences in indexes related predominantly peripheral involvement, such as tender and swollen joint counts, enthesitis score and presence of dactylitis.

Conclusion: This study demonstrates a higher prevalence of MetS in PsA patients compared to TA. It also suggests that MetS might be associated with high disease activity and more severe disease especially in patients with axial involvement.

Table 1. Clinical features and disease activity parameters in PsA patients with and without MetS.

PsA Patients with MetS

(n:47)

PsA Patients without MetS

(n:57)

p value

Age(mean , yrs)

55.49

47.28

0.001

Sex (F%)

34/47 (72%)

32/57 (%56)

0.88

Smoking (%)

None

Exsmoker

Active smoker

25/47 (53%)

13/47 (27%)

9/47 (19%)

17/57 (29%)

14/57 (24%)

26/57 (45%)

0.016

BMI (med, IQR)

30.3 (6.6)

26.4 (5.9)

<0.001

Disease duration (yrs) (med/IQR)

7 (6)

9 (8)

0.386

BASDAI (med, IQR)

22 (34)

11 (25)

0.042

BASFI(med, IQR)

18 (36)

5 (14)

0.009

BASMI (med, IQR)

20 (20)

10 (20)

0.001

VAS (med, IQR)

31 (33)

20 (31)

0.030

DAS28(med, IQR)

2.6 (1.2)

2.1 (1.4)

0.059

PASI (med, IQR)

0.1 (4.8)

1.5 (7.2)

0.164

CPDAI (med, IQR)

6.3 (6.0)

3.6 (7.4)

0.049

ASqOL (med, IQR)

7 (8)

3.0 (6)

0.017

DLQI (med, IQR)

0 (4)

1 (2)

0.794

ASDAS (med, IQR)

2.5 (1.8)

1.7 (1.2)

0.008

HAQ (med, IQR)

0.375 (1.125)

0.125 (0.438)

0.011

VAS physician

(med, IQR)

16 (17)

13 (16)

0.151

DAPSA (med, IQR)

15.8 (13.4)

10.6 (19.9)

0.190

Tender joint count (med, IQR)

1(2) min:0 max:9

0 (1) min:0 max:6

0.31

Swollen joint count (med, IQR)

0 (1) min:0 max:5

0 (1)min:0 max: 4

0.83

ESR (med, IQR)

(mm /h)

11(13)

10 (15)

0.478

CRP (med,IQR)(mg/L)

5.5 (9.6)

3.8 (5.6)

0.280

Dactylitis (n, %)

2/47 (4.2%)

7/56 (12.5%)

0.140

Enthesitis (n, %)

3/46(6.5%)

6/56 (10.7%)

0.458

Uveitis (n, %)

1/47(2.1%)

2/56 (3.5%)

0.664

Syndesmophytes

22/36 (61%)

16/44 (36%)

0.027

Sacroilitis (radiographic)(n,%)

8/44 (18%)

13/53 (24%)

0.296

Hand X-ray erosions (n, %)

12/31 (38%)

14/37 (37%)

0.589

Hand X-ray osteoproliferation

(n, %)

9/31 (29%)

10/37 (27%)

0.589

Obesity/ overweigt (n, %)

44/47 (93%)

35/57(61%)

0.000

İnflammatory back pain (n, %)

19/47 (40.4%)

23/57 (40.3%)

0.99

SIJ MRI positivity (active sacroilitis)

(n, %)

9/13 (69%)

10/18 (55%)

0.44


Disclosure: P. Sanci, None; G. Kenar, None; B. Zengin, None; S. Uslu, None; A. Koken, None; H. Yarkan, None; G. Can, None; M. Birlik, None; F. Onen, None.

To cite this abstract in AMA style:

Sanci P, Kenar G, Zengin B, Uslu S, Koken A, Yarkan H, Can G, Birlik M, Onen F. Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/metabolic-syndrome-is-associated-with-active-disease-in-psoriatic-arthritis-and-may-contribute-to-development-of-syndesmophytes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-syndrome-is-associated-with-active-disease-in-psoriatic-arthritis-and-may-contribute-to-development-of-syndesmophytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology